Hemab Therapeutics Holdings (NASDAQ: COAG) saw its stock gain 10.5% on Friday after announcing that it will present nine separate items of scientific data at the International Society on Thrombosis and Haemostasis (ISTH) 2026 Congress, scheduled for July 11-15, 2026 in Paris.
The clinical-stage biotechnology firm, with operations in Cambridge, Massachusetts and Copenhagen, will use the conference to display new results spanning its portfolio of therapies aimed at blood coagulation disorders. The planned presentations include first-in-human findings for HMB-002 in Von Willebrand disease, long-term extension data for sutacimig in Glanzmann thrombasthenia, and preclinical results for a recently disclosed program, HMB-003.
HMB-002's first-in-human dataset provided proof of mechanism in Von Willebrand disease, demonstrating increases in Von Willebrand Factor and Factor VIII following subcutaneous dosing. The company reports that a multiple dose assessment of HMB-002 is currently underway.
Hemab described HMB-003 as a peptide plasmin inhibitor developed to act as an antifibrinolytic agent to reduce bleeding. The company intends to begin first-in-human studies for HMB-003 in the second half of 2026 and to prepare clinical evaluations in heavy menstrual bleeding during 2027.
Long-term extension data for sutacimig indicated a sustained reduction in the annualized treated bleeding rate among patients with Glanzmann thrombasthenia. Regulatory designations have been granted for the program - the U.S. Food and Drug Administration conferred Breakthrough Therapy designation on sutacimig, while the European Medicines Agency awarded Priority Medicines designation.
Hemab plans to start Phase 3 studies of sutacimig in the second half of 2026. The company also noted that preclinical work supporting sutacimig will underpin an expansion into treatment of Factor VII deficiency, where a Phase 2b study is currently in progress.
Taken together, the presentations at ISTH 2026 are intended to highlight progress across Hemab's pipeline of therapies targeting coagulation disorders. Several programs are advancing into additional clinical assessments or preparing to initiate human testing within the timelines the company disclosed.
Conference: International Society on Thrombosis and Haemostasis 2026 Congress, Paris, July 11-15, 2026
Key programs to be presented: HMB-002 (first-in-human, Von Willebrand disease); sutacimig (long-term extension, Glanzmann thrombasthenia; Phase 3 planned H2 2026; Phase 2b in progress for Factor VII deficiency); HMB-003 (preclinical; first-in-human planned H2 2026; heavy menstrual bleeding studies planned 2027).